| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10219951 | European Urology | 2018 | 7 Pages |
Abstract
Metastasectomy is recommended for some patients with metastatic clear-cell kidney cancer; however, we do not know who will benefit the most. We show that molecular subtypes increase the possibility to predict which patients are at risk for early relapse after metastasectomy and who may benefit more from other treatment options.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Annelies Verbiest, Gabrielle Couchy, Sylvie Job, Laure Caruana, Evelyne Lerut, Raymond Oyen, Aurélien de Reyniès, Lorenzo Tosco, Steven Joniau, Hendrik Van Poppel, Dirk Van Raemdonck, Kathleen Van Den Eynde, Agnieszka Wozniak, Jessica Zucman-Rossi,